NKTR—I listened to the JPM/Q&A replay. Evidently, the PROPEL (bempeg + Keytruda) study in 1L-NSCLC does not violate the “Competing Combination” clause from the amended BMY-NKTR agreement you excerpted in #msg-153233793 because NKTR is characterizing PROPEL as a 100%-NKTR study rather than a collaboration with MRK. (Note that MRK is not displayed as a NKTR partner anywhere in the JPM slide set.)
All told, the NKTR 20-minute Q&A session was unusually informative, IMO. It revealed how colossally chaotic the bempeg development program has become and how much time and expense has been squandered by the manufacturing screw-up and the various changes in trial design.
Despite all the hiccups, I still think bempeg is likely to be an approvable drug. Do you agree?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.